Tag: GlobeNewswire

Reports Quarterly Asset Growth of 2.1% and Net Originations of $37.1 Million, Including Two New Portfolio Companies

Non-Accruals Remain Low at 0.0% of Fair Value and 1.3% of Cost

Repurchase of 444,124 Shares, Contributing $0.09 Per Share of NAV Accretion

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — Saratoga Investment Corp. (NYSE: SAR) (“Saratoga Investment” or “the Company”), a business development company (“BDC”), today announced financial results for its fiscal second quarter 2027 ended August 31, 2026.

Summary Financial Information
The Company’s summarized financial information is as follows:

	For the three months ended and as of
($ in thousands, except per share)	August 31, 2026	May 31, 2026	August 31, 2025
Assets Under Management (AUM)	1,150,190	1,126,334	995,295
Net Asset Value (NAV)	352,577	378,455	410,500
NAV per share	22.15	23.23	25.61
Total Investment Income	31,169	30,777	30,626
Net Investment Income (NII) per share	0.45	0.47	0.58
Adjusted NII per share	0.46	0.47	0.58
Earnings per share	(0.41)	(0.42)	0.84
Dividends per share (record date)	0.75	0.75	0.75
Return on Equity – last twelve months	(1.1%)	4.0%	9.1%
– annualized quarter	(7.3%)	(7.1%)	13.8%
Originations	76,113	79,151	52,222
Repayments	39,048	48,415	29,824

Positive highlights during and subsequent to the quarter include:

• High-quality AUM growth of 2.1% sequentially, including two new non-software portfolio companies,
• Issuance of an $85.0 million SAX baby bond, which subsequent to quarter-end increased to $120.8 million through exercise of the green shoe and reopening of the issuance. This issuance allowed for refinancing of the $105.5 million SAT baby bond, reducing refinancing risk for next year. Opportunistically issued prior to Labor Day and subsequent increases in interest rates and competitive offerings,
• Repurchases of 444,124 shares at a discount to NAV resulting in a $0.09 per share NAV per share accretion,
• Took advantage of robust refinancing environment to reset CLO1 at $350 million at lower rates, three-year reinvestment period, future BDC management fees and significantly improved interest income,
• Significant Zollege investment appreciation, and
• Both Pepper Palace and the CLO F-Note have been sold post quarter-end, thereby eliminating all remaining non-accrual investments, and recently our Exigo red investment was also fully exited at $8.0 million, resulting in a -6.1% IRR over the life of the investment.

Headwinds during the quarter:

• Balance sheet refinancing resulting in additional interest expense from higher cost debt while spreads on assets not yet widening, although recent base rate increases will benefit interest income,
• NAV per share decline includes $0.82 per share specifically related to company performance in three distinct credits, and $0.30 per share related to dividend distributions exceeding net investment income, offset by $0.09 per share appreciation from share repurchases, and
• $13.3 million of $25.9 million NAV decline from accretive share repurchases (32%) and excess dividend distribution (19%) of previously undistributed earnings, which reduces the Company spillover obligation.

Christian L. Oberbeck, Chairman and Chief Executive Officer of Saratoga Investment, commented, “Our second-quarter results demonstrate the resilience of our platform despite the continued pressure affecting private credit markets. We grew assets under management by 2.1% to $1.150 billion, generating $37.1 million of net originations, while adjusted NII remained relatively stable at $0.46 per share including the cost of our recently refinanced capital structure. Although company-specific valuation adjustments, most previously highlighted in Q1, reduced NAV during the quarter, our core BDC portfolio ended the period only 1.6% below cost, and non-accrual investments represented 0.0% of total portfolio fair value and 1.3% of cost, with both the F-Note and Pepper Palace being sold after quarter-end. We believe these results reflect the underlying quality of the overall portfolio and our ability to continue deploying capital selectively in a volatile market.”

“Continuing our track record of strong dividend distributions, we recently announced a base monthly dividend of $0.25 per share, or $0.75 per share in aggregate for the third quarter of fiscal 2027. Our annualized third quarter dividend of $0.75 per share represents an 18.1% yield based on the stock price of $16.61 as of October 5, 2026, offering strong current income. Originations and AUM growth during the quarter contributed to adjusted NII of $0.46 per share, compared to $0.47 per share last quarter. The modest sequential decline reflected higher interest income from portfolio growth, including new originations and BB and BBB CLO debt investments, offset by the full-period impact of our recent refinancing activity.”

“Investment activity remained healthy during the quarter, supported by the continued expansion of our business development capabilities and sponsor relationships. Market dynamics continued to be very competitive. Despite this, we originated $76.1 million of investments, including investments in two new portfolio companies and nine follow-on investments, compared with $39.0 million of repayments, resulting in $37.1 million of net originations. Approximately $9.2 million of the quarter’s originations consisted of BB and BBB CLO debt investments. While competition remains significant and sentiment across private credit continues to be cautious, we remain highly selective and disciplined in evaluating opportunities given the uncertain operating environment. Our strong reputation, differentiated market positioning, and the ongoing development of sponsor relationships continue to create attractive investment opportunities from high-quality sponsors. We remain prudent and discerning in our underwriting approach, particularly in light of the current volatile and uncertain environment.”

“Saratoga’s overall performance is reflected in our key performance indicators this past quarter and year, including: (i) an increase in AUM of $23.9 million, or 2.1%, to $1.150 billion from the previous quarter, and $154.9 million, or 15.6%, from the previous year, (ii) NAV decrease of $25.9 million, or 6.8%, to $352.6 million from the previous quarter, with 49% of the decline due to portfolio adjustments and 51% due to excess dividend distributions and share repurchases, (iii) LTM ROE of (1.1)% as compared to the industry average of 2.2%, (iv) adjusted NII of $0.46 versus $0.47 per share last quarter, (v) EPS of $(0.41) per share versus $(0.42) in the previous quarter, and (vi) total dividends of $0.75 per share, unchanged from last quarter and last year.”

“NAV per share is down by 4.6% from $23.23 per share last quarter to $22.15 per share in Q2. Of the $1.08 per share reduction this quarter, $0.90 per share was attributable to unrealized depreciation on investments discussed below, and $0.30 per share distribution of dividends in excess of earnings, partially offset by $0.09 per share of accretion from net share repurchases.”

“Our total $1.150 billion portfolio was marked down $14.4 million during the quarter from realized gains and unrealized depreciation. The non-CLO portfolio had $15.4 million of net depreciation, driven primarily by $13.1 million of markdowns in Madison Logic, Exigo and Chronus, reflecting company performance adjustments, and the sales of Gen4 and Modis that resulted in a $1.5 million reversal of previously recognized unrealized appreciation, while other marks reflected a combination of lower equity market multiples and changes in market spreads. These declines were partially offset by $4.5 million of unrealized appreciation in Zollege. The CLO1’s F Note remained at zero fair value, the JV was written down $1.1 million, representing primarily the effect of $0.8 million of dividend income that reduced fair value, and the BB and BBB portfolio was relatively flat. We also recognized $2.1 million of realized gains, primarily from the Gen4 and Modis Dental equity conversions as part of a merger transaction. At quarter-end, our core BDC portfolio was 1.6% below cost and the total portfolio was 4.9% below cost.”

“During the quarter, our core non-CLO net interest margin increased by $0.2 million to $13.6 million. The average core assets increase of 1.2% and 5 basis points increase in the average SOFR rate used in the portfolio, was offset by (i) spreads on originations this quarter being 220 basis points lower than the repayments they replaced, and (ii) increased interest expense due to changes in our capital structure. Shares issued under the DRIP were fully offset by share repurchases, resulting in no net dilution.”

“Our quarter-end cash position increased from $60.8 million last quarter to $95.9 million, and used subsequent to quarter-end to redeem the $105.5 million SAT baby bond that was called.”

“Our overall credit quality remained solid this quarter, with 96.0% of credits rated in our highest internal category, a result we are proud of given the current headwinds in the industry, as further seen in this quarter’s markdowns. Pepper Palace and our CLO’s F Note remained on non-accrual and at zero fair value, together representing 0.0% of portfolio fair value and 1.3% of portfolio cost. With 81.5% of our investments at quarter-end in first lien debt, generally supported by strong enterprise values and resilient balance sheets in industries that have historically performed well in stressed situations, we believe our portfolio composition and leverage profile are well structured to handle a wide range of economic conditions and uncertainty.”

Mr. Oberbeck concluded, “As we reach the halfway point of fiscal year 2027, the operating environment remains uneven as geopolitical uncertainty, persistent inflation, interest-rate volatility and concerns regarding AI-related disruption within the software sector continue to affect borrowers and valuations. These conditions have contributed to higher default activity, declining NAVs across the industry and dividend reductions by several BDCs. At Saratoga, however, the NAV decline this quarter was concentrated in a limited number of company-specific situations and does not appear to reflect broad-based deterioration across the portfolio. At the same time, strong BDC debt issuance, firmer values for higher-quality loans and improving M&A activity point to a market that appears to be stabilizing and increasingly differentiating among managers. We remain confident that our disciplined, senior secured, first-lien focused underwriting and well-structured balance sheet position Saratoga to navigate this environment and continue delivering durable, risk-adjusted returns to our shareholders over the long term.”

Discussion of Financial Results for the Quarter ended August 31, 2026:

• AUM at fair value as of August 31, 2026 was $1.150 billion, an increase of 2.1% from $1.126 billion as of last quarter, and an increase of 15.6% from $995.3 million as of August 31, 2025.
• Total investment income for the three months ended August 31, 2026, was $31.2 million, an increase of $0.6 million, or 2.0%, from $30.6 million for the quarter ended August 31, 2025, and an increase of $0.4 million, or 1.3%, as compared to $30.8 million for the quarter ended May 31, 2026. This quarter’s investment income increase, as compared to prior quarters, was primarily due to the full-quarter impact of Q1 originations and the partial-quarter impact of Q2 originations more than offsetting repayments. Investment income reflects a weighted average interest rate on the core BDC portfolio of 10.6%, up from 10.5% as of May 31, 2026 and down from 11.3% as of August 31, 2025, and starting to reflect recent SOFR base rate increases.
• Total expenses for the quarter ended August 31, 2026, excluding interest and debt financing expenses, base management fees and incentive fees, and income and excise taxes, were $2.9 million, an increase of $0.4 million compared to $2.5 million for the quarter ended August 31, 2025, and an increase of $0.2 million as compared to $2.7 million for the quarter ended May 31, 2026. This represented 0.9% of average total assets on an annualized basis, unchanged from 0.9% last quarter and up from 0.8% last year.
• Adjusted NII for the quarter ended August 31, 2026, was $7.4 million, or $0.46 per share, compared with $9.1 million, or $0.58 per share, for the quarter ended August 31, 2025 and $7.6 million, or $0.47 per share, for the quarter ended May 31, 2026. The modest sequential decline primarily reflected the impact of the recent changes to the capital structure increasing interest expense, as well as (i) slight decreases in other income from lower structuring, advisory and prepayment fees, and (ii) higher base management fees from higher AUM.
• NII Yield as a percentage of average net asset value for the quarter ended August 31, 2026, was 8.0%. Adjusted NII Yield was 8.1%, as compared to adjusted NII Yield of 9.0% last year, and 7.8% last quarter.
• NAV was $352.6 million as of August 31, 2026, a decrease of $57.9 million from $410.5 million as of August 31, 2025, and a decrease of $25.9 million from $378.5 million as of May 31, 2026.
• NAV per share was $22.15 as of August 31, 2026, compared to $23.23 as of May 31, 2026, and $25.61 as of August 31, 2025.
• Return on equity (“ROE”) for the last twelve months ended August 31, 2026, was (1.1%), compared with 9.1% for the comparable period last year, and 4.0% for the twelve months ended May 31, 2026. ROE on an annualized basis for the quarter ended August 31, 2026 was (7.3)%.
• Repurchased 444,124 shares of common stock under our Share Repurchase Plan at an average price of $18.91 per share for approximately $8.4 million during the quarter. The shares were repurchased below NAV, generating approximately $0.11 per share of NAV accretion and fully offsetting shares issued under the Company’s dividend reinvestment plan.
• The weighted average common shares outstanding for the quarter ended August 31, 2026 was 16.2 million, down from 16.3 million shares last quarter and increasing from 15.8 million for the quarter ended August 31, 2025.

Portfolio and Investment Activity for the Quarter Ended August 31, 2026

• Fair value of Saratoga Investment’s portfolio was $1.150 billion, excluding $95.9 million in cash and cash equivalents, principally invested in 50 portfolio companies, one collateralized loan obligation fund (the “CLO”), one joint venture fund (the “JV”), and 32 distinct BB and BBB CLO debt investments.
• Cost of investments made during the quarter ended August 31, 2026 were $76.1 million, including two investments in new portfolio companies and nine follow-on investments. Cost of investments made during the six months ended August 31, 2026 were $155.3 million.
• Principal repayments during the quarter ended August 31, 2026, were $39.0 million, including two full debt repayments and equity realizations, four partial repayments, plus amortization. Principal repayments for the six months ended August 31, 2026 were $87.5 million.
  • For the quarter ended August 31, 2026, the fair value of the portfolio decreased by $14.4 million of net realized gains and unrealized depreciation, consisting primarily of (i) $15.4 million of net depreciation in the non-CLO core portfolio, (ii) a $1.1 million write down in the JV, and (iii) $2.1 million of net realized gains, primarily from the Gen4 and Modis Dental equity conversions.
  • The $15.4 million of net depreciation in the non-CLO core portfolio consisted primarily of three components:
    • Madison Logic, Exigo and Chronus continued to decline and represented $13.1 million of the quarter’s write-downs;
    • The equity conversions of Gen4 and Modis resulted in a $1.5 million reversal of previously recognized unrealized appreciation; and
    • The remaining portfolio marks reflected numerous lower equity market multiples in certain equity positions and the impact of changes in market spreads across the portfolio, offset by $4.5 million of unrealized appreciation in Zollege.
  • Since taking over management of the BDC in 2010, the Company has generated $1.41 billion of repayments and sales of investments originated by Saratoga Investment, generating a gross unlevered IRR of 14.9%. Total investments originated by Saratoga are $2.66 billion in 134 portfolio companies.
• The overall portfolio composition consisted of 81.5% of first lien term loans, 3.9% of second lien term loans, 1.4% of unsecured loans, 6.1% of structured finance securities, and 7.1% of common equity.
• The weighted average current yield on Saratoga Investment’s portfolio based on current fair values was 9.9%, which was comprised of a weighted average current yield of 10.5% on first lien term loans, 12.0% on second lien term loans, 11.4% on unsecured loans, 10.9% on structured finance securities and 0.0% on equity interests.
• On September 17, 2026, the Company completed the sixth refinancing of the Saratoga CLO. This refinancing, among other things, extended the Saratoga CLO reinvestment period to October 2029, extended its legal maturity to October 2037, and established a non-call period ending in April 2028. This new Saratoga CLO will have approximately $350 million in assets. As part of this refinancing, we invested an additional $16.2 million in newly issued subordinated notes of the Saratoga CLO and purchased $2.6 million in aggregate principal amount of its Class E-2-R5 notes tranche at par.

Liquidity and Capital Resources

Outstanding Borrowings:

• On August 26, 2026, we issued $85.0 million in aggregate principal amount of 8.00% fixed-rate notes due 2031 (the “8.00% 2031 Notes”) for net proceeds of approximately $82.3 million. Estimated offering costs incurred were approximately $0.3 million. Interest on the 8.00% 2031 Notes is paid quarterly on February 28, May 31, August 31 and November 30 of each year, with the first payment to be made on November 30, 2026. The Notes will mature on August 31, 2031. The 8.00% 2031 Notes may be redeemed in whole or in part at any time or from time to time at the Company’s option on or after August 26, 2028. The Company has granted the underwriters an option to purchase up to an additional $12.75 million in aggregate principal amount of Notes, and on September 2, 2026, the underwriters fully exercised their option for net proceeds to the Company of $12.4 million after deducting underwriting commissions of approximately $0.4 million. In addition, on September 24, 2026, the Company issued an additional $23.1 million in aggregate principal amount of its 8.00% Notes due 2031, including $3.0 million pursuant to the underwriters’ exercise in full of their over-allotment option. Net proceeds to the Company were $22.5 million, based on the public offering price of 99.6% of the aggregate principal amount, after deducting underwriting commissions of approximately $0.5 million and estimated offering expenses of $0.2 million. The Notes are listed on the NYSE under the trading symbol “SAX”. The Company has received an investment grade private rating of “BBB” from Egan-Jones Ratings Company, an independent, unaffiliated rating agency.
• As of August 31, 2026 Saratoga Investment had $902.4 million of borrowings outstanding, including $32.5 million under its $85.0 million senior secured revolving Valley Credit Facility and $37.5 million under its $75.0 million senior secured revolving Live Oak Credit Facility.
• In addition, Saratoga Investment had $84.0 million of SBA debentures in its SBIC II license outstanding, $129.0 million of SBA debentures in its SBIC III license outstanding, $454.4 million of listed baby bonds issued, $75.0 million of unsecured unlisted institutional bond issuances, four unlisted private issuances of $90.0 million in total, and an aggregate of $95.9 million in cash and cash equivalents.
• On September 18, 2026, the Company redeemed, in full, $105.5 million aggregate principal amount of the issued and outstanding 6.00% 2027 Notes. The 6.00% 2027 Notes were redeemed at 100% of their principal amount, plus the accrued and unpaid interest thereon, through, but excluding, the date of redemption.

Undrawn Borrowing Capacity:

• With $90.0 million available under the two credit facilities and $95.9 million of cash and cash equivalents as of August 31, 2026, Saratoga Investment has a total of $185.9 million of undrawn credit facility borrowing capacity and cash and cash equivalents available, however this cash and the additional bond proceeds raised on September 2, 2026 is to be used for the repayment of the 6.00% 2027 Notes. The available credit facility can be used for new investments or to support existing portfolio companies in the BDC and the SBIC.
• In addition, Saratoga Investment has $46.0 million in undrawn SBA debentures available from its existing SBIC III license. And in May 2026, legislation amending the Small Business Investment Act of 1958 increased the individual SBIC leverage limit from $175.0 million to $250.0 million, and the maximum leverage available for two or more SBICs under common control from $350.0 million to $475.0 million, in each case subject to SBA approvals. On September 4, 2026, the Company received notification from the SBA that SBIC III’s individual leverage limit was increased to $250.0 million, providing an additional $75.0 million of long-term capital in the form of SBA-guaranteed debentures.
• Availability under the Valley National Bank and Live Oak credit facilities can change depending on portfolio company performance and valuation. In addition, certain follow-on investments in SBIC II and the BDC will not qualify for SBIC III funding.
• Total Saratoga Investment undrawn borrowing capacity is therefore $136.0 million as of August 31, 2026.
• As of August 31, 2026, Saratoga Investment had $120.0 million of committed undrawn lending commitments and $61.1 million of discretionary funding commitments.

Additionally:

• Saratoga Investment has an active equity distribution agreement with Ladenburg Thalmann & Co. Inc., Raymond James and Associates, Inc, Lucid Capital Markets, LLC and Compass Point Research and Trading, LLC, through which the Company may offer for sale, from time to time, up to $300.0 million of common stock through an ATM offering.
  • As of August 31, 2026, Saratoga Investment has sold 8,591,915 shares for gross proceeds of $227.2 million at an average price of $26.42 for aggregate net proceeds of $225.4 million (net of transaction costs).
  • During the three and six months ended August 31, 2026, Saratoga Investment did not sell any shares through its ATM Program.

Dividend

On September 9, 2026, Saratoga Investment announced that its Board of Directors declared a base quarterly dividend of $0.75 per share in aggregate for the third quarter of fiscal 2027, declaring the following three monthly $0.25 per share dividends:

Month		Amount Per Share			Record Date		Payment Date
September 2026		$0.25			October 6, 2026		October 22, 2026
October 2026		$0.25			November 5, 2026		November 24, 2026
November 2026		$0.25			December 3, 2026		December 22, 2026

Shareholders have the option to receive payment of dividends in cash or receive shares of common stock, pursuant to the Company’s DRIP. Shares issued under the Company’s DRIP are issued at a 5% discount to the average market price per share at the close of trading on the ten trading days immediately preceding (and including) the payment date.

The following table highlights Saratoga Investment’s monthly dividend distribution for fiscal 2027 and annual distribution over the past five years:

Period (Fiscal Year ends Feb)	Base Dividend Per Share		Special Dividend Per Share	Total Dividend Per Share
Fiscal Q3 2027 (November 2026)	$0.25		–	$0.25
Fiscal Q3 2027 (October 2026)	$0.25		–	$0.25
Fiscal Q3 2027 (September 2026)	$0.25		–	$0.25
Fiscal Q2 2027 (August 2026)	$0.25		–	$0.25
Fiscal Q2 2027 (July 2026)	$0.25		–	$0.25
Fiscal Q2 2027 (June 2026)	$0.25		–	$0.25
Fiscal Q1 2027 (May 2026)	$0.25		–	$0.25
Fiscal Q1 2027 (April 2026)	$0.25		–	$0.25
Fiscal Q1 2027 (March 2026)	$0.25		–	$0.25
Total Declared in Fiscal 2027 YTD	$2.25		–	$2.25
Full Year Fiscal 2026	$3.00		$0.25	$3.25
Full Year Fiscal 2025	$2.96		$0.35	$3.31
Full Year Fiscal 2024	$2.86		–	$2.86
Full Year Fiscal 2023	$2.44		–	$2.44

Share Repurchase Plan

As of August 31, 2026, the Company purchased 1,481,822 shares of common stock, at the average price of $21.11 for approximately $31.3 million pursuant to the Share Repurchase Plan. During the three and six months ended August 31, 2026, the Company purchased 444,124 shares of common stock, at an average price of $18.91 for approximately $8.4 million pursuant to the Share Repurchase Plan.

Previously, in fiscal year 2015, the Company announced the approval of an open market share repurchase plan (the “Share Repurchase Plan”) that allows it to repurchase up to 200,000 shares of its common stock at prices below its NAV as reported in its then most recently published financial statements. Since then, the Share Repurchase Plan has been extended annually, and the Company has periodically increased the amount of shares of common stock that may be purchased under the Share Repurchase Plan, most recently to 2.7 million shares of common stock. On January 6, 2026, its Board of Directors extended the Share Repurchase Plan for another year to January 15, 2027.

Fiscal Second Quarter 2027 Conference Call/Webcast Information

When:	Wednesday, October 7, 2026
	10:00 a.m. Eastern Time (ET)
How:	Webcast: Interested parties may access a live webcast of the call and find the Q2 2027 presentation by going to the “Events & Presentations” section of Saratoga Investment Corp.’s investor relations website, Saratoga events and presentations. A replay of the webcast will also be available for a limited time at Saratoga events and presentations.
Call:	To access the call by phone, please go to the Registration Link, and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

About Saratoga Investment Corp.

Saratoga Investment is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Saratoga Investment’s objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments. Saratoga Investment has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended, and is externally managed by Saratoga Investment Advisors, LLC, an SEC-registered investment advisor focusing on credit-driven strategies. Saratoga Investment Corp. owns two active SBIC-licensed subsidiaries, having surrendered its first license after repaying all debentures for that fund following the end of its investment period and subsequent wind-down. Furthermore, it manages a $350 million collateralized loan obligation (“CLO”) fund that has recently repriced and reset its reinvestment period and co-manages a joint venture (“JV”) fund that owns a $400 million collateralized loan obligation (“JV CLO”) fund.  It also owns 50% of the Class E2R5 notes and 100% of the subordinated notes of the CLO, 87.5% of both the unsecured loans and membership interests of the JV and 87.5% of the Class E-R notes of the JV CLO. The Company’s diverse funding sources, combined with a permanent capital base, enable Saratoga Investment to provide a broad range of financing solutions.

Forward Looking Statements

This press release contains historical information and forward-looking statements with respect to the business and investments of the Company, including, but not limited to, the statements about future events or our future performance or financial condition. Forward-looking statements can be identified by the use of forward looking words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or negative versions of those words, other comparable words or other statements that do not relate to historical or factual matters. The forward-looking statements are based on our beliefs, assumptions and expectations of our future performance, taking into account all information currently available to us. These statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including, but not limited to: changes in the markets in which we invest; changes in the financial, capital, and lending markets; an economic downturn or a recession and its impact on the ability of our portfolio companies to operate and the investment opportunities available to us; the impact of interest rate volatility on our business and our portfolio companies; the uncertainty associated with the imposition of tariffs and trade barriers and changes in trade policy and its impact on our portfolio companies and the global economy; the impact of supply chain constraints and labor shortages on our portfolio companies; and the elevated levels of inflation and its impact on our portfolio companies and the industries in which we invest, as well as those described from time to time in our filings with the Securities and Exchange Commission.

Any forward-looking statement speaks only as of the date on which it is made. The Company undertakes no duty to update any forward-looking statements made herein or on the webcast/conference call, whether as a result of new information, future developments or otherwise, except as required by law. Readers should not place undue reliance on any forward-looking statements and are encouraged to review the Company’s Annual Report on Form 10-K for the fiscal year ended February 28, 2026 and subsequent filings, including the “Risk Factors” sections therein, with the Securities and Exchange Commission for a more complete discussion of the risks and other factors that could affect any forward-looking statements. 

Contacts:
Saratoga Investment Corporation
535 Madison Avenue, 4th Floor
New York, NY 10022

Henri Steenkamp
Chief Financial Officer
Saratoga Investment Corp.
212-906-7800
                                                             
Lena Cati
The Equity Group Inc.
Lena.Cati@theequitygroup.com
212-836-9611

Val Ferraro
The Equity Group Inc.
Val.Ferraro@theequitygroup.com
212-836-9633

Financials

Saratoga Investment Corp.
Consolidated Statements of Assets and Liabilities
		August 31, 2026				February 28, 2026
		(unaudited)
ASSETS
Investments at fair value
Non-control/Non-affiliate investments (amortized cost of $1,082,091,998 and $1,011,840,007, respectively)		$	1,056,184,544			$	1,016,247,566
Affiliate investments (amortized cost of $49,910,512 and $49,429,192, respectively)			49,257,789				52,710,911
Control investments (amortized cost of $77,083,090 and $75,118,675, respectively)			44,748,011				40,175,335
Total investments at fair value (amortized cost of $1,209,085,600 and $1,136,387,874, respectively)			1,150,190,344				1,109,133,812
Cash and cash equivalents			80,087,303				1,680,070
Cash and cash equivalents, reserve accounts			15,786,427				20,105,683
Interest receivable (net of reserve of $1,265,898 and $470,751, respectively)			9,122,307				7,314,053
Management fee receivable			229,150				249,720
Other assets			847,327				781,766
Total assets		$	1,256,262,858			$	1,139,265,104
LIABILITIES
Revolving credit facilities		$	70,000,000			$	70,000,000
Deferred debt financing costs, revolving credit facilities			(1,236,703	)			(1,670,816	)
SBA debentures payable			213,000,000				160,000,000
Deferred debt financing costs, SBA debentures payable			(4,792,550	)			(3,888,087	)
4.35% Notes Payable 2027			75,000,000				75,000,000
Discount on 4.35% notes payable 2027			(41,071	)			(108,898	)
Deferred debt financing costs, 4.35% notes payable 2027			(170,781	)			(344,393	)
6.25% Notes Payable 2027			15,000,000				15,000,000
Deferred debt financing costs, 6.25% notes payable 2027			(94,894	)			(130,839	)
6.00% Notes Payable 2027			105,500,000				105,500,000
Discount on 6.00% notes payable 2027			(27,924	)			(48,361	)
Deferred debt financing costs, 6.00% notes payable 2027			(470,739	)			(823,774	)
8.00% Notes Payable 2027			46,000,000				46,000,000
Deferred debt financing costs, 8.00% notes payable 2027			(405,603	)			(580,514	)
8.125% Notes Payable 2027			60,375,000				60,375,000
Deferred debt financing costs, 8.125% notes payable 2027			(543,519	)			(748,873	)
8.50% Notes Payable 2028			57,500,000				57,500,000
Deferred debt financing costs, 8.50% notes payable 2028			(661,105	)			(866,230	)
7.25% Notes Payable 2029			25,000,000				–
Discount on 7.25% notes payable 2029			(442,158	)			–
Deferred debt financing costs, 7.25% notes payable 2029			(115,176	)			–
7.25% Notes Payable 2030			50,000,000				50,000,000
Discount on 7.25% notes payable 2030			(394,008	)			(435,318	)
Deferred debt financing costs, 7.25% notes payable 2030			(777,418	)			(775,165	)
7.50% Notes Payable 2031			100,000,000				100,000,000
Deferred debt financing costs, 7.50% notes payable 2031			(3,171,759	)			(3,298,905	)
8.00% Notes Payable 2031			85,000,000				–
Deferred debt financing costs, 8.00% notes payable 2031			(2,884,102	)			–
Base management and incentive fees payable			6,893,075				6,602,819
Deferred tax liability			3,600,349				4,579,522
Accounts payable and accrued expenses			853,687				1,771,915
Interest and debt fees payable			5,537,756				3,904,143
Directors fees payable			–				5,500
Due to Manager			622,572				590,624
Current income tax payable			33,106				–
Total liabilities			903,686,035				743,109,350
Commitments and contingencies
NET ASSETS
Common stock, par value $0.001, 100,000,000 common shares
authorized, 15,915,928 and 16,224,198 common shares issued and outstanding, respectively			15,916				16,224
Capital in excess of par value			433,529,752				439,202,477
Total distributable deficit			(80,968,845	)			(43,062,947	)
Total net assets			352,576,823				396,155,754
Total liabilities and net assets		$	1,256,262,858			$	1,139,265,104
NET ASSET VALUE PER SHARE		$	22.15			$	24.42
Asset Coverage Ratio			171.9	%			168.4	%

	Saratoga Investment Corp.
	Consolidated Statements of Operations
	(unaudited)
			For the three months ended
			August 31, 2026				August 31, 2025
	INVESTMENT INCOME
	Interest from investments
	Interest income:
	Non-control/Non-affiliate investments		$	26,680,966			$	23,697,449
	Affiliate investments			710,089				684,587
	Control investments			687,577				1,191,555
	Payment in kind interest income:
	Non-control/Non-affiliate investments			176,321				121,084
	Affiliate investments			524,784				604,880
	Control investments			19,829				77,880
	Total interest from investments			28,799,566				26,377,435
	Interest from cash and cash equivalents			441,110				2,360,397
	Management fee income			101,090				663,632
	Dividend income:
	Non-control/Non-affiliate investments			369,276				127,689
	Control investments			752,370				903,439
	Total dividend from investments			1,121,646				1,031,128
	Structuring and advisory fee income			563,616				221,600
	Other income			142,196				(28,436	)
	Total investment income			31,169,224				30,625,756
	OPERATING EXPENSES
	Interest and debt financing expenses			14,061,404				12,372,030
	Base management fees			5,065,837				4,374,324
	Incentive management fees expense (benefit)			1,827,237				2,271,173
	Professional fees			626,850				649,899
	Administrator expenses			1,350,000				1,283,333
	Insurance			80,598				74,310
	Directors fees and expenses			125,103				118,500
	General and administrative			680,951				412,769
	Income tax expense (benefit)			46,080				(11,315	)
	Total operating expenses			23,864,060				21,545,023
	NET INVESTMENT INCOME			7,305,164				9,080,733
	REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMENTS
	Net realized gain (loss) from investments:
	Non-control/Non-affiliate investments			2,057,105				52,691
	Net realized gain (loss) from investments			2,057,105				52,691
	Income tax (provision) benefit from realized gain on investments			(71,949	)			–
	Net change in unrealized appreciation (depreciation) on investments:
	Non-control/Non-affiliate investments			(18,387,829	)			478,796
	Affiliate investments			(1,515,830	)			139,577
	Control investments			3,439,596				3,109,340
	Net change in unrealized appreciation (depreciation) on investments			(16,464,063	)			3,727,713
	Net change in provision for deferred taxes on unrealized (appreciation) depreciation on investments			512,564				423,998
	Net realized and unrealized gain (loss) on investments			(13,966,343	)			4,204,402
	NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS		$	(6,661,179	)		$	13,285,135
	WEIGHTED AVERAGE – BASIC AND DILUTED EARNINGS (LOSS) PER COMMON SHARE		$	(0.41	)		$	0.84
	WEIGHTED AVERAGE COMMON SHARES OUTSTANDING – BASIC AND DILUTED			16,155,202				15,775,387

	Saratoga Investment Corp.
	Consolidated Statements of Operations
	(unaudited)
			For the six months ended
			August 31, 2026				August 31, 2025
	INVESTMENT INCOME
	Interest from investments
	Interest income:
	Non-control/Non-affiliate investments		$	52,686,744			$	49,162,112
	Affiliate investments			1,436,183				1,280,211
	Control investments			1,374,293				2,382,216
	Payment in kind interest income:
	Non-control/Non-affiliate investments			349,612				289,313
	Affiliate investments			1,028,394				1,189,629
	Control investments			39,415				77,880
	Total interest from investments			56,914,641				54,381,361
	Interest from cash and cash equivalents			995,496				4,387,608
	Management fee income			646,078				1,368,807
	Dividend income:
	Non-control/Non-affiliate investments			369,276				689,872
	Control investments			1,531,222				1,339,857
	Total dividend from investments			1,900,498				2,029,729
	Structuring and advisory fee income			1,219,979				485,975
	Other income			269,457				290,893
	Total investment income			61,946,149				62,944,373
	OPERATING EXPENSES
	Interest and debt financing expenses			27,711,687				24,823,895
	Base management fees			10,035,890				8,707,656
	Incentive management fees expense (benefit)			3,719,298				4,807,686
	Professional fees			1,158,086				1,349,099
	Administrator expenses			2,700,000				2,533,333
	Insurance			161,196				148,620
	Directors fees and expenses			251,103				250,000
	General and administrative			1,281,217				1,058,180
	Income tax expense (benefit)			29,521				43,139
	Total operating expenses			47,047,998				43,721,608
	NET INVESTMENT INCOME			14,898,151				19,222,765
	REALIZED AND UNREALIZED GAIN (LOSS) ON INVESTMENTS
	Net realized gain (loss) from investments:
	Non-control/Non-affiliate investments			1,568,957				2,315,675
	Control investments			638,355				638,355
	Net realized gain (loss) from investments			2,207,312				2,954,030
	Income tax (provision) benefit from realized gain on investments			(71,949	)			–
	Net change in unrealized appreciation (depreciation) on investments:
	Non-control/Non-affiliate investments			(30,315,013	)			850,944
	Affiliate investments			(3,934,442	)			93,633
	Control investments			2,608,261				3,727,113
	Net change in unrealized appreciation (depreciation) on investments			(31,641,194	)			4,671,690
	Net change in provision for deferred taxes on unrealized (appreciation) depreciation on investments			1,043,388				368,913
	Net realized and unrealized gain (loss) on investments			(28,462,443	)			7,994,633
	NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS		$	(13,564,292	)		$	27,217,398
	WEIGHTED AVERAGE – BASIC AND DILUTED EARNINGS (LOSS) PER COMMON SHARE		$	(0.84	)		$	1.75
	WEIGHTED AVERAGE COMMON SHARES OUTSTANDING – BASIC AND DILUTED			16,203,415				15,560,114

Supplemental Information Regarding Adjusted Net Investment Income, Adjusted Net Investment Income Yield and Adjusted Net Investment Income per Share

On a supplemental basis, Saratoga Investment provides information relating to adjusted net investment income, adjusted net investment income yield and adjusted net investment income per share, which are non-GAAP measures. These measures are provided in addition to, but not as a substitute for, net investment income, net investment income yield and net investment income per share, respectively. These non-GAAP measures should only be used to evaluate the Company’s results of operations in conjunction with their corresponding GAAP measures. Adjusted net investment income represents net investment income excluding any capital gains incentive fee expense or reversal attributable to realized and unrealized gains. The management agreement with the Company’s advisor provides that a capital gains incentive fee is determined and paid annually with respect to cumulative realized capital gains (but not unrealized capital gains) to the extent such realized capital gains exceed realized and unrealized losses for such year. In addition, Saratoga Investment accrues, but does not pay, a capital gains incentive fee in connection with any unrealized capital appreciation, as appropriate. All capital gains incentive fees are presented within net investment income within the Consolidated Statements of Operations, but the associated realized and unrealized gains and losses that these incentive fees relate to, are excluded. As such, Saratoga Investment believes that adjusted net investment income, adjusted net investment income yield and adjusted net investment income per share is a useful indicator of operations exclusive of any capital gains incentive fee expense or reversal attributable to gains. In addition, adjusted net investment income in fiscal 2027 also excludes the interest expense and amortization of deferred financing costs related to the 8.0% 2031 Notes during the period while the 6.0% 2027 Notes were already issued and outstanding. This expense is directly attributable to the issuance of the 8.0% 2031 Notes and the subsequent repayment of the 6.0% 2027 Notes, and this double interest expense is deemed to be non-recurring in nature and not representative of the operations of Saratoga Investment. The presentation of this additional information is not meant to be considered in isolation or as a substitute for financial results prepared in accordance with GAAP, and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles.  Pursuant to the requirements of Item 10(e) of Regulation S-K, the following table provides a reconciliation of net investment income to adjusted net investment income, net investment income yield to adjusted net investment income yield and net investment income per share to adjusted net investment income per share for the three and six months ended August 31, 2026 and 2025.

	For the Three Months Ended
	August 31, 2026	August 31, 2025
Net Investment Income	$7,305,164	$9,080,733
Changes in accrued capital gains incentive fee expense/ (reversal)	–	–
Interest on 8.0% 2031 Notes	122,810	–
Adjusted net investment income	$7,427,974	$9,080,733
Net investment income yield	8.0%	9.0%
Changes in accrued capital gains incentive fee expense/ (reversal)	–	–
Interest on 8.0% 2031 Notes	0.1%	–
Adjusted net investment income yield (1)	8.1%	9.0%
Net investment income per share	$0.45	$0.58
Changes in accrued capital gains incentive fee expense/ (reversal)	–	–
Interest on 8.0% 2031 Notes	$0.01	–
Adjusted net investment income per share (2)	$0.46	$0.58

(1)   Adjusted net investment income yield is calculated as adjusted net investment income divided by average net asset value.
(2)   Adjusted net investment income per share is calculated as adjusted net investment income divided by weighted average common shares outstanding.

	For the Six Months Ended
	August 31, 2026	August 31, 2025
Net Investment Income	$14,898,151	$19,222,765
Changes in accrued capital gains incentive fee expense/ (reversal)	–	–
Interest on 8.0% 2031 Notes	122,810	–
Adjusted net investment income	$15,020,961	$19,222,765
Net investment income yield	7.9%	9.6%
Changes in accrued capital gains incentive fee expense/ (reversal)	–	–
Interest on 8.0% 2031 Notes	0.1%	–
Adjusted net investment income yield (3)	8.0%	9.6%
Net investment income per share	$0.92	$1.24
Changes in accrued capital gains incentive fee expense/ (reversal)	–	–
Interest on 8.0% 2031 Notes	$0.01	–
Adjusted net investment income per share (4)	$0.93	$1.24

(3)   Adjusted net investment income yield is calculated as adjusted net investment income divided by average net asset value.
(4)   Adjusted net investment income per share is calculated as adjusted net investment income divided by weighted average common shares outstanding.

New preclinical data further characterizes EQ504’s coordinated effects across epithelial and immune compartments in intestinal inflammation

LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in a poster at the 50^th Anniversary La Jolla Immunology Conference, taking place October 6-8, 2026 in La Jolla, California.

“These data provide additional insight into the multi-modal activity of EQ504, demonstrating coordinated effects across epithelial and immune compartments that preserve barrier integrity while resolving inflammation,” said Dr. Stephen Connelly, Chief Scientific Officer of Equillium. “We believe these complementary effects are particularly relevant to ulcerative colitis, where both reducing inflammation and improving mucosal healing are important to achieving meaningful outcomes for patients.”

Details of the poster presentations:

Title: AhR activation stabilizes inflammatory crosstalk and promotes barrier repair in an intestinal co-culture model
Poster Number: I-37
Lead Author: Rosa Quinn Closser
Presentation Type: Poster Session 1
Date: October 6, 2026
Time: 11:00am to 1:00pm PT
Presentation Summary: EQ504 demonstrated coordinated effects across epithelial and immune compartments in an intestinal co-culture model, preserving barrier integrity while suppressing inflammatory cytokine production. These findings further support the potential of EQ504 to address both barrier dysfunction and inflammation in ulcerative colitis.

Following the presentation, the poster will be available on the Presentations page located under the Technology section of equilliumbio.com.

About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.

About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.

For more information, visit www.equilliumbio.com.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s plans and strategies with respect to developing EQ504, including the initiation of clinical studies and the reporting of data therefrom; the expected timeline for initiating and reporting data from a Phase 1 study of EQ504; and the potential benefits of EQ504. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical and pre-clinical studies; whether the results from clinical and pre-clinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; and Equillium’s ability to raise sufficient financing, which may not be available on acceptable terms or at all, to advance EQ504 and fund Equillium’s strategic plans. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in Equillium’s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com

SAN DIEGO, Oct. 06, 2026 (GLOBE NEWSWIRE) — LPL Financial Holdings Inc. (Nasdaq: LPLA) (the “Company”), the parent corporation of LPL Financial LLC, announced today it will report third quarter financial results after the market closes on Tuesday, October 27. The Company will host a conference call to discuss its results at 5 p.m. ET the same day.

The conference call will be accessible and available for replay at investor.lpl.com/events.

Contacts

Investor Relations
investor.relations@lplfinancial.com

Media Relations
media.relations@lplfinancial.com

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”) and LPL Enterprise, LLC (“LPL Enterprise”), both registered investment advisors and broker-dealers. Members FINRA/SIPC.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial or LPL Enterprise.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

ROCHESTER, N.Y., Oct. 06, 2026 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ), a leading U.S.-based total beverage alcohol company, today reported its second quarter fiscal 2027 financial results. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Nicholas Fink, and Chief Financial Officer, Garth Hankinson, on Wednesday, October 7, 2026, at 8:00 a.m. ET. Visit ir.cbrands.com to locate information for joining the conference call, or a live, listen-only webcast of the conference call.

ABOUT CONSTELLATION BRANDS
Constellation Brands (NYSE: STZ), a leading U.S.-based company, is an international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Our mission is to build brands that people love because we believe elevating human connections is Worth Reaching For. It’s worth our dedication, hard work, and calculated risks to anticipate market trends and deliver for our consumers, shareholders, employees, and industry. This dedication is what has driven us to become one of the fastest-growing, large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what’s next.

Every day, people reach for brands from our high-end, imported beer portfolio anchored by the iconic Corona Extra and Modelo Especial, a flavorful lineup of Modelo Cheladas, and favorites like Pacifico, and Victoria; our exceptional wine brands including The Prisoner Wine Company, Robert Mondavi Winery, Kim Crawford, Schrader Cellars, and Lingua Franca; and our craft spirits brands such as Mi CAMPO Tequila and High West Whiskey.

As an agriculture-based company, we strive to operate in a way that is sustainable and responsible. Our ESG strategy is embedded into our business and we focus on serving as good stewards of the environment, investing in our communities, and promoting responsible beverage alcohol consumption. We believe these aspirations in support of our longer-term business strategy allow us to contribute to a future that is truly Worth Reaching For.

To learn more, visit www.cbrands.com and follow us on LinkedIn and Instagram.

MEDIA CONTACTS	INVESTOR RELATIONS CONTACTS
Maggie Bowman 213-500-2401 / maggie.bowman@cbrands.com Carissa Guzski 315-525-7362 / carissa.guzski@cbrands.com	Blair Veenema 585-284-4433 / blair.veenema@cbrands.com David Paccapaniccia 585-282-7227 / david.paccapaniccia@cbrands.com Emily Blanchard 585-765-5181 / emily.blanchard@cbrands.com

A PDF containing our second quarter fiscal 2027 financial results and full financial tables is available at: 

http://ml.globenewswire.com/Resource/Download/f7d23faa-8640-4efa-8700-18fc330cce76

 

Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease

Two poster presentations will highlight preclinical research supporting the therapeutic potential of SLC6A19 inhibition in chronic kidney disease

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that the company will present data supporting its lead programs, MZE829 and MZE782, during the American Society of Nephrology (ASN) Kidney Week, being held October 21–25, 2026, in Denver, Colorado.

Maze will deliver an oral presentation of previously reported data, updated to include additional details from the Phase 2 HORIZON trial evaluating MZE829 in patients with APOL1-mediated kidney disease (AMKD). In addition, the company will present two preclinical posters highlighting research that further supports SLC6A19 inhibition, the mechanism underlying MZE782, as a potential therapeutic approach for chronic kidney disease (CKD).

“ASN Kidney Week is an important opportunity to engage with the nephrology community and highlight the progress we are making across our kidney disease portfolio,” said Jason Coloma, Ph.D., chief executive officer of Maze. “We look forward to presenting the initial HORIZON results for MZE829 that we reported earlier this year, which demonstrated encouraging clinical activity in patients with AMKD. Together with the preclinical research supporting MZE782, these presentations underscore our commitment to advancing new precision medicines for patients with kidney disease.”

Details of the presentations are as follows:

Oral Presentation: 
Title: [SA-OR053] Evaluation of Safety, Tolerability, and Efficacy of MZE829 in Adults with APOL1-Mediated Kidney Disease (HORIZON Study)
Date and Time: October 24, 2026; 5:40 PM to 5:50 PM MT
Presenter: Opeyemi A. Olabisi, M.D., Ph.D., Chief of the Nephrology Division and Associate Professor of Medicine, Duke University School of Medicine

Poster Presentations: 
Title: [FR-PO0215] A New Role for SLC6A19 Inhibition: Reducing Uptake of Nephrotoxins to Limit Kidney Injury
Date and Time: October 23, 2026; 10:00 AM to 12:00 PM MT

Title: [TH-PO0213] SLC6A19 Inhibition Drives a Protective Proximal Tubule Metabolic State Complementary to SGLT2 Inhibition
Date and Time: October 22, 2026; 10:00 AM to 12:00 PM MT

About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the company’s future plans and prospects, any expectations regarding the safety or efficacy of MZE829, MZE782 and other candidates under development, the ability of MZE829 to treat AMKD or other indications, the ability of MZE782 to treat PKU, CKD or other indications, the planned timing of the company’s clinical trials, data results and further development of MZE829, MZE782 and other therapeutic candidates, including the initial HORIZON results, and the company’s ability to advance its pipeline toward late-stage clinical development. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “will,” “predict” and similar expressions and their variants, as they relate to the company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the company believes the expectations reflected in such forward-looking statements are reasonable, the company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the company’s forward-looking statements due to a variety of factors, including risks and uncertainties related to the company’s ability to advance MZE829, MZE782 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the company’s therapeutic candidates, the timing and results of preclinical studies and clinical trials, the company’s ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its business of macroeconomic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises. Further information on potential risk factors that could affect the company’s business and its financial results is detailed under the heading “Risk Factors” included in the documents the company files from time to time with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

IR/Corporate Contact:
Argot Partners
maze@argotpartners.com

Media Contact:
Amanda Lazaro, 1AB Media
amanda@1ABMedia.com

SEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that its board of directors approved stock option grants to purchase an aggregate of 46,500 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 44,500 shares of its common stock for four new employees. Achieve also announced that the board of directors approved an inducement award grant to Benjamin Halladay, the Company’s newly appointed Chief Financial Officer, consisting of an option to purchase up to 200,000 shares of common stock and 200,000 RSUs.

The stock options have an exercise price equal to the closing price of Achieve’s common stock on the applicable grant date. Each stock option has a ten-year term and vests over four years, with 25% of the shares underlying the stock option on the first anniversary following commencement of employment. The remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to the employee’s continued service through each applicable vesting date.

Each RSU award represents the right to receive one share of Achieve’s common stock upon vesting, subject to the recipient’s continued service. The RSUs will vest over four years with 25% of the underlying shares vesting on each anniversary following commencement of employment, subject to the employee’s continued service through each applicable vesting date.

The stock options and RSU awards are subject to the terms and conditions of the 2024 Equity Inducement Plan, as well as the terms and conditions of the stock option agreement or RSU award agreement covering the grants and were made as an inducement material to the individuals entering into employment with Achieve in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and reducing the reward and satisfaction associated with nicotine products.

About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the timing, nature and outcome of cytisinicline clinical development and regulatory review and approval, data results, the timing, nature and success of Achieve’s commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, the performance of Achieve’s third-party manufacturing partners, the successful launch and commercialization of cytisinicline, the use of proceeds from Achieve’s private placement, and statements concerning Achieve Life Sciences’ future plans and prospects. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those described in Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Achieve Contact
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
media@achievelifesciences.com
425-686-1510

Reference
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM Evidence, doi: 10.1056/EVIDpha2500339.

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional evidence from the Phase 3 CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) will be shared at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting, taking place in Boston, Massachusetts on October 9-12, 2026.

BridgeBio will present the effects of encaleret on patient-reported outcomes and on bone turnover from the Phase 3 CALIBRATE trial. In partnership with the HypoPARAthyroidism Association, BridgeBio will also share findings from regional family cascade genetic testing events that evaluated a proband-initiated model designed to bring no-cost genetic testing and counseling directly to at-risk relatives in their home region.

BridgeBio will also have a poster featuring data showing a lack of peripheral FGFR1 inhibition at clinically relevant infigratinib exposures, supporting the safety profile observed in children with achondroplasia in the PROPEL clinical program.

ADH1 Oral Presentations:
Encaleret Restores Mineral Homeostasis and Increases Bone Turnover in Autosomal Dominant Hypocalcemia Type 1 (ADH1): 24-Week Results from Phase 3 CALIBRATE Trial
Presenter: Erik A. Imel, M.D., Indiana University School of Medicine
Date: Sunday, October 11 at 11:42 am EDT

Participant-Reported Changes in Symptoms and Treatment Experience with Encaleret in Autosomal Dominant Hypocalcemia Type 1: 24-Week Findings from the Phase 3 CALIBRATE Trial
Presenter: Steven W. Ing, M.D., Ohio State University Wexner Medical Center
Date: Sunday, October 11 at 11:54 am EDT

ADH1 Posters:
Baseline Symptom Burden and Impact on Daily Functioning in Autosomal Dominant Hypocalcemia Type 1: Exit Interview Findings from the Phase 3 CALIBRATE Trial
Presenter: Susan Martin, MSPH, RTI Health Solutions
Date: Saturday, October 10 at 2:00 pm EDT

Family Cascade Genetic Testing for Autosomal Dominant Hypocalcemia Type 1: A Multi-Stakeholder Regional Event Model
Presenter: Mark Warren, M.D., Physicians East, Greenville, NC
Date: Saturday, October 10 at 2:00 pm EDT

Achondroplasia Poster:
Lack of Peripheral FGFR1 Inhibition at Clinically Relevant Infigratinib Exposures Supports the Safety Profile Observed in Children with Achondroplasia
Presenter: Bhavik Shah, BridgeBio Skeletal Dysplasias
Date: Sunday, October 11 at 2:00 pm EDT

About Autosomal Dominant Hypocalcemia Type 1 (ADH1)
ADH1 is a common form of genetic hypoparathyroidism caused by gain-of-function variants in the calcium-sensing receptor gene (CASR). The calcium-sensing receptor (CaSR) constantly monitors and balances blood calcium levels by regulating parathyroid hormone secretion and calcium reabsorption in the kidneys. Individuals with ADH1 typically experience hypocalcemia, hypercalciuria, and inappropriately low levels of PTH. Symptoms of hypocalcemia may include severe muscle cramps, muscle spasms (tetany), a burning or prickling sensation in the hands or feet (paresthesia), brain fog, fatigue, and seizures. Hypercalciuria may result in kidney calcification (nephrocalcinosis), kidney stones (nephrolithiasis), and kidney failure.

About Encaleret
Encaleret is an investigational, orally administered small molecule under investigation to treat ADH1 and chronic hypoparathyroidism that is designed to selectively negatively modulate the calcium-sensing receptor. Encaleret has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation in the U.S., European Union, and Japan.

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650) 789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

ST. PETERSBURG, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — American Coastal Insurance Corporation (Nasdaq Ticker: ACIC) (“the Company”, “American Coastal” or “ACIC”), the insurance holding company of American Coastal Insurance Company (“AmCoastal”), today announced that it will host an investor webcast presentation on Tuesday, October 13, 2026, at 2:00 p.m. Eastern Time.

During the webcast, Bradford Martz, President and Chief Executive Officer, and Svetlana Castle, Chief Financial Officer, will conduct an introductory presentation covering key aspects of American Coastal’s business, including corporate strategy, business model, and growth initiatives. After the formal presentation, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.

Participants can register here: https://us02web.zoom.us/webinar/register/WN_EnFhLKfxSHOHPdkmKwpuoQ

A link to the webcast will also be available on American Coastal’s investor relations website at https://investors.amcoastal.com.

About American Coastal Insurance Corporation:
American Coastal Insurance Corporation (amcoastal.com) is the holding company of the insurance carrier, American Coastal Insurance Company, which was founded in 2007 for the purpose of insuring Condominium and Homeowner Association properties, Apartments and Assisted Living Facilities in the state of Florida. American Coastal Insurance Company has an exclusive partnership for distribution of Condominium Association properties in the state of Florida with AmRisc Group (amriscgroup.com), one of the largest Managing General Agents in the country specializing in hurricane-exposed properties. American Coastal Insurance Company has earned an “A”, (“Exceptional”) Financial Stability Rating from Demotech and maintains an “A” insurance financial strength rating with a Stable outlook from KBRA. ACIC maintains a “BBB” issuer rating with a Stable outlook from KBRA.

Contact Information:                
Alexander Baty                
Vice President, Finance & Investor Relations, American Coastal Insurance Corporation
investorrelations@amcoastal.com
(727) 425-8076        

Glen Akselrod
President & Founder, Bristol Investor Relations
ga@bristolir.com
(905) 326-1888

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that one oral presentation, three rapid-fire oral presentations, and six poster presentations on acoramidis in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) will be shared at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2026, taking place in Phoenix, Arizona on October 9-12, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

Acoramidis is approved as Attruby^® by the U.S. FDA and is approved as BEYONTTRA^® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, and the Brazilian Health Regulatory Agency (ANVISA) with all labels specifying near-complete stabilization of TTR.

Oral Presentation:
Association Between the Burden of Cardiovascular-Related Hospitalizations and All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy: Insights from ATTRibute-CM
Presenter: Quan Bui, M.D., UC San Diego Health, U.S.
Date/time: Saturday, October 10 at 7:45 am MST

Rapid-Fire Oral Presentations:
Real-World Comparative Effectiveness Study of Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy Using the Epic COSMOS Data Platform
Presenter: David Lanfear, M.D., M.S., Chief Scientific Officer of Henry Ford Health, U.S.
Date/time: Sunday, October 11 at 11:30 am MST

Early eGFR Dip Following Acoramidis Initiation is Associated with Reduced Risk of Mortality and Recurrent Cardiovascular-Related Hospitalizations in ATTR-CM
Presenter: Ahmad Masri, M.D., M.S., Oregon Health & Science University, U.S.
Date/time: Sunday, October 11 at 11:12 am MST

Ratio of Serum Transthyretin to NT-proBNP is a Novel Prognostic Measure for Transthyretin Amyloid Cardiomyopathy: Insights from ATTRibute-CM
Presenter: James L. Januzzi, M.D., Massachusetts General Hospital, U.S.
Date/time: Sunday, October 11 at 10:45 am MST

Poster Presentations:
Falls and Fractures Drive Increased Hospitalizations and Costs in Patients with Transthyretin Amyloid Cardiomyopathy Compared with Controls
Presenter: Nitasha Sarswat, M.D., University of Chicago, U.S.
Date/time: Friday, October 9 at 6:15 pm MST

Evaluating the Long-Term Effects of Acoramidis on Cardiac Function, Structure, and Amyloid Burden in Transthyretin Amyloid Cardiomyopathy: ASCEND-ATTR
Presenter: Ahmad Masri, M.D., M.S., Oregon Health & Science University, U.S.
Date/time: Saturday, October 10 at 1:45 pm MST

Real-World Burden of Transthyretin Amyloid Cardiomyopathy Disease and Outcomes in Patients on Tafamidis Prior to Initiating Acoramidis
Presenter: Richard Wright, M.D., Pacific Heart Institute, U.S.
Date/time: Saturday, October 10 at 5:45 pm MST

Acoramidis Reduces Risk of Cardiovascular-Related Mortality and Hospitalization in Women with Transthyretin Amyloid Cardiomyopathy
Presenter: Margot Davis, M.D., University of British Columbia, CA
Date/time: Saturday, October 10 at 6:15 pm MST

Acoramidis Preserves Functional Capacity and Quality of Life in p.Val142Ile Variant Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM
Presenter: Lily Stern, M.D., Cedars-Sinai Heart Institute, U.S.
Date/time: Sunday, October 11 at 8:15 am MST

Effect of Acoramidis on Heart Failure-Related Health Status Before and After Cardiovascular-Related Hospitalization: Insights from ATTRibute-CM
Presenter: Ahmad Masri, M.D., M.S., Oregon Health & Science University, U.S.
Date/time: Sunday, October 11 at 8:15 am MST

About Attruby^® (acoramidis)

INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650) 789-8220

BridgeBio Investor Contact:
Kristen Kelleher, Director, Investor Relations
ir@bridgebio.com

Mechelen, Belgium; October 06, 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (“Lakefront”) announces that between September 28, 2026, and October 02, 2026, it has repurchased 117,437 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchase	Market/MTF	Number of shares	Average price paid (€)	Total (€)	Lowest price paid (€)	Highest price paid (€)
09/ 28/2026	XAMS	17,470	25.77	450,287.50	25.52	26.04
09/28/2026	TQEX	1,388	25.80	35,816.09	25.74	25.98
09/28/2026	CEUX	2,710	25.76	69,813.94	25.64	26.04
09/28/2026	AQEU	1,729	25.72	44,472.47	25.62	25.98
09/29/2026	XAMS	17,899	26.20	469,014.66	26.00	26.34
09/29/2026	TQEX	1,007	26.24	26,421.57	26.16	26.36
09/29/2026	CEUX	4,148	26.26	108,936.44	26.16	26.34
09/29/2026	AQEU	89	26.22	2,333.70	26.16	26.26
09/30/2026	XAMS	16,365	26.23	429,293.23	26.02	26.40
09/30/2026	TQEX	1,532	26.31	40,304.62	26.16	26.34
09/30/2026	CEUX	5,539	26.26	145,479.62	26.12	26.40
09/30/2026	AQEU	134	26.24	3,516.40	26.12	26.28
10/01/2026	XAMS	19,341	25.99	502,662.92	25.64	26.34
10/01/2026	TQEX	572	26.08	14,916.10	26.00	26.16
10/01/2026	CEUX	3,661	26.03	95,289.61	25.68	26.16
10/01/2026	AQEU	136	25.97	3,532.06	25.68	26.04
10/02/2026	XAMS	20,391	25.72	524,372.92	25.36	25.96
10/02/2026	TQEX	277	25.62	7,096.19	25.58	25.70
10/02/2026	CEUX	2,943	25.68	75,586.54	25.34	25.90
10/02/2026	AQEU	106	25.66	2,719.96	25.66	25.66
Total		117,437	25.99	3,051,866.51	25.34	26.40

As of market close on October 02, 2026, Lakefront holds 1,751,031 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com
  

Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com

 Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Attachment

• 20261002 LakefrontEN RNS Announcement